Skip to main content
    S

    Skye Bioscience, Inc. Common Stock (SKYE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.00
    -0.07 (-6.10%)

    Market Cap: $4.83M

    Last updated: Nov 17, 2026 at 4:10 PM ET

    Skye Bioscience, Inc. Common Stock (SKYE) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Skye Bioscience, Inc. Common Stock (SKYE) has a market cap of $4.83M. It earned -$37.67M on revenue of $0 over the last 12 months.

    Total Valuation

    Market Cap$4.83M
    Latest price (Nov 17, 2026)$1.00

    Key Dates

    The next earnings report is expected on Mar 8, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 8, 2027 (expected)
    Last Earnings DateNov 13, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.69% in the quarter ended Sep 30, 2026 and grew 1.45% a year over 2 years.

    Shares Outstanding4.99M
    Shares Change (YoY)+0.73%
    Shares Change (QoQ)+0.69%
    Share Count Growth (2Y CAGR)+1.45%

    Price Statistics

    The stock is down 90.38% over 52 weeks and trades 34.21% below its 50-day average.

    Beta (1Y)0.61
    52-Week Change-90.38%
    1-Month Change-34.64%
    3-Month Change-59.14%
    6-Month Change-82.76%
    5-Year Change-99.11%
    10-Year Change-99.90%
    Total Return (1Y)-90.38%
    Total Return (3Y CAGR)-58.42%
    Total Return (5Y CAGR)-61.89%
    Return vs SPY (1Y)-102.16%
    Max Drawdown (1Y)-93.84%
    Max Drawdown (3Y)-99.52%
    Sharpe Ratio (1Y)-2.34
    Correlation with SPY (1Y)0.08
    50-Day Average$1.52
    200-Day Average$4.44
    52-Week Range$0.26 to $2.25
    RSI (14 Days)37.6
    Average Volume (20 Days)122.95K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 1.36x current liabilities.

    Current Ratio1.36x
    Quick Ratio1.36x

    Returns and Efficiency

    Return on equity is -2768.93% and return on assets is -742.59% over the last 12 months.

    Return on Equity (ROE)-2768.93%
    Return on Assets (ROA)-742.59%

    Scores

    SKYE has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.

    Piotroski F-Score1 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $0 over the last 12 months.

    Revenue$0
    Operating Income-$43.60M
    Pretax Income-$37.67M
    Net Income-$37.67M
    Reported EPS (TTM)-$6.10

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 26.82% of the $5.07M in total assets.

    Cash and Equivalents$4.82M
    Working Capital$1.32M
    Shareholder Equity$1.36M
    Book Value Per Share$0.27
    Total Assets$5.07M
    Total Liabilities$3.71M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $9 of capital spending, operating cash flow left -$30.58M of free cash flow.

    Operating Cash Flow-$30.58M
    Capital Expenditures$9
    Free Cash Flow-$30.58M
    FCF Per Share-$6.91
    Depreciation and Amortization$541.82K

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Stock Splits

    The last split was a 1-for-8 reverse split on Aug 24, 2026.

    Last Split DateAug 24, 2026
    Split TypeReverse split
    Split Ratio1:8

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About SKYE

    What is SKYE's market cap?

    Skye Bioscience, Inc. Common Stock has a market cap of $4.83M.

    How many shares of SKYE are outstanding?

    Skye Bioscience, Inc. Common Stock has 4.99M shares outstanding. The count is up 0.73% from a year earlier.

    Does SKYE pay a dividend?

    No. Skye Bioscience, Inc. Common Stock does not pay a dividend.